Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

(2012) L Robertson et al.   BRITISH JOURNAL OF CANCER

19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus

(2012) K. N. Stevens et al.   CANCER RESEARCH

Microfluidic Amplification as a Tool for Massive Parallel Sequencing of the Familial Hypercholesterolemia Genes

(2012) S. Hollants et al.   CLINICAL CHEMISTRY

No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways

(2012) Judith Penkert et al.   Familial Cancer

BRCA2 Mutations and Triple-Negative Breast Cancer

(2012) Peter Meyer et al.   PLoS One

Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

(2011) E. Comen et al.   BREAST CANCER RESEARCH AND TREATMENT

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

(2011) Soley Bayraktar et al.   BREAST CANCER RESEARCH AND TREATMENT

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

(2011) Anne-Renee Hartman et al.   CANCER

Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer

(2011) S. Casadei et al.   CANCER RESEARCH

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer

(2011) Heide Hellebrand et al.   HUMAN MUTATION

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

(2011) D. G. Evans et al.   JOURNAL OF MEDICAL GENETICS

Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population

(2010) O. Lavie et al.   ANNALS OF ONCOLOGY

Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk

(2010) Amanda I. Phipps et al.   BREAST CANCER RESEARCH AND TREATMENT

PALB2 mutations in German and Russian patients with bilateral breast cancer

(2010) Natalia Bogdanova et al.   BREAST CANCER RESEARCH AND TREATMENT

Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer

(2010) Elizabeth A. Comen et al.   CANCER JOURNAL

BRD7, a Subunit of SWI/SNF Complexes, Binds Directly to BRCA1 and Regulates BRCA1-Dependent Transcription

(2010) M. T. Harte et al.   CANCER RESEARCH

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Expanding the Criteria forBRCAMutation Testing in Breast Cancer Survivors

(2010) Janice S. Kwon et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Triple-negative breast cancer: Present challenges and new perspectives

(2010) Franca Podo et al.   Molecular Oncology

BRD7 is a candidate tumour suppressor gene required for p53 function

(2010) Jarno Drost et al.   NATURE CELL BIOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

(2009) SR Young et al.   BMC CANCER

The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype

(2009) T. Heikkinen et al.   CLINICAL CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer

(2008) Deann P. Atchley et al.   JOURNAL OF CLINICAL ONCOLOGY